TRAnscranial Doppler CErebral Blood Flow and Cognitive IMPAIRment in Heart Failure
Launched by JOHN PAUL II HOSPITAL, KRAKOW · Feb 10, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The TRACE-IMPAIR trial is a study looking at how heart failure might affect thinking and memory skills in patients, especially in relation to blood flow in the brain. Researchers will use special ultrasound techniques to measure blood flow in the carotid arteries (the ones in your neck) and the brain, and they will also conduct simple tests to check how well participants can think and remember.
To take part in this study, participants should be stable patients with heart failure for at least six months, meaning their symptoms are under control. They will need to agree to a few tests, including heart imaging and cognitive assessments. Unfortunately, those with serious other health issues, severe dementia, or recently had a stroke will not be eligible. If you join, you can expect to contribute to important research that may help understand the connection between heart health and brain health, with support from the medical team throughout the process.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinically stable patients (NYHA I-III symptoms) with HF (for at least 6 months) either of ischemic or inflammatory etiology as well as genetic cardiomyopathies
- • Signed informed consent form
- • Consent to imaging studies: echocardiography, carotid and transcranial Doppler sonography and neuropsychological tests (MMSE and MoCA).
- Exclusion Criteria:
- • Co-existing, severe, irreversible disease (e.g. advanced cancer)
- • Previously diagnosed dementia (including severe dementia - MMSE and MoCA score \<10)
- • Psychiatric condition which may influence cognitive function
- • Acute, decompensated HF
- • Reversible cause of HF - tachyarrhytmic, peripartum or toxic cardiomyopathy, acute myocarditis, acute myocardial infarction
- • Aortic stenosis
- • Cerebral stroke in the preceding 3 months
- • Lack of transcranial Doppler acoustic window
- • Echocardiographic projections precluding adequate measurements
- • Anemia with Hemoglobin \< 8 g/dl
- • Alcohol or psychoactive agents abuse
About John Paul Ii Hospital, Krakow
John Paul II Hospital in Krakow is a leading healthcare institution dedicated to advancing medical research and improving patient care through innovative clinical trials. Renowned for its commitment to excellence, the hospital leverages cutting-edge technologies and a multidisciplinary approach to facilitate groundbreaking studies across various medical fields. With a team of experienced professionals and a focus on ethical standards, John Paul II Hospital aims to contribute to the development of effective treatments and therapies, enhancing the overall health outcomes for patients locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kraków, Mp, Poland
Patients applied
Trial Officials
Piotr Musialek, MD, DPhil
Principal Investigator
John Paul II Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials